Citius Oncology announced a commercial update for its U.S. launch of LYMPHIR™, highlighting strong institutional uptake, broad payer coverage representing ~80% of covered lives, and expanding clinical development collaborations.
Key takeaways
83% of target accounts have added or are actively progressing LYMPHIR through formulary review, indicating strong institutional adoption.
Market access secured with ~135 health plans representing ~80% of covered lives, with no reported reimbursement denials or prior authorization barriers.
Sequential growth in orders observed with initial accounts placing repeat orders, supporting early prescribing continuity.
Clinical development expanding through investigator-sponsored studies at University of Minnesota and UPMC for broader oncology indications.
International expansion underway through executed distribution agreements across Europe and the Middle East.